Jefferies Maintains a 'Buy' on Synta Pharma. (SNTA); Market Reaction Excessive
Tweet Send to a FriendGet Alerts SNTA Hot Sheet
Price: $7.31 -1.08%
Rating Summary:
6 Buy, 3 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 21 | Down: 24 | New: 29
Rating Summary:
6 Buy, 3 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 21 | Down: 24 | New: 29
Trade SNTA Now!
Jefferies maintains a 'Buy' on Synta Pharma. (NASDAQ: SNTA) price target of $14.00.
Analyst, Thomas Wei, said, "The two promising GALAXY subgroups alluded to in May were high LDH and adenocarcinoma, not mKRAS. The adenocarcinoma overall survival data appear compelling, while we see mKRAS data as too early to be definitive. Separately, we believe ganetespib will not be developed further in squamous likely due to bleeding. The similarity to the Avastin profile suggests this issue may be isolated to squamous histology. We remain buyers on weakness."
For an analyst ratings summary and ratings history on Synta Pharma. click here. For more ratings news on Synta Pharma. click here.
Shares of Synta Pharma. closed at $4.82 yesterday, with a 52 week range of $3.02-$8.50.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Analyst, Thomas Wei, said, "The two promising GALAXY subgroups alluded to in May were high LDH and adenocarcinoma, not mKRAS. The adenocarcinoma overall survival data appear compelling, while we see mKRAS data as too early to be definitive. Separately, we believe ganetespib will not be developed further in squamous likely due to bleeding. The similarity to the Avastin profile suggests this issue may be isolated to squamous histology. We remain buyers on weakness."
For an analyst ratings summary and ratings history on Synta Pharma. click here. For more ratings news on Synta Pharma. click here.
Shares of Synta Pharma. closed at $4.82 yesterday, with a 52 week range of $3.02-$8.50.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Topeka Capital Upgrades Pacific Sunwear of California (PSUN) to Buy
- Canaccord Genuity Boosts Price Target on Akamai (AKAM) Citing Momentum
- MKM Partners Lifts PT on KB Home (KBH) After Management Meetings
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
Jefferies & Co
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
